XML 50 R37.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of Significant Accounting Policies (Details Narrative) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
Jul. 31, 2018
May 31, 2018
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Dec. 31, 2017
Net loss     $ 2,514 $ 5,692 $ 3,505 $ 9,214  
Accumulated deficit     (92,341)   (92,341)   $ (88,836)
Net cash used in operating activities         723 $ (8,509)  
Cash resources and restricted investments     6,315   6,315    
Restricted cash     200   200   $ 200
Right of use asset     2,300   2,300    
Lease liability     $ 2,800   2,800    
Surface Pharmaceuticals Inc [Member]              
Net loss         $ 891    
Ownership percentage     30.00%   30.00%    
Gain on deconsolidation of Surface Pharmaceuticals         $ 5,320    
Number of shares owned     3,500,000   3,500,000    
Investment losses     $ 128   $ 230    
Investment in surface     $ 5,090   $ 5,090    
Surface Series A Stock [Member]              
Proceeds from issuance of preferred stock $ 21,000 $ 21,000          
Surface Series A Stock [Member] | Surface Pharmaceuticals Inc [Member]              
Ownership percentage     35.00%   35.00%    
Share purchase price     $ 3.30   $ 3.30    
Restricted Stock Units [Member]              
Number of shares vested during the period         202,603 121,344  
Deferred Acquisition Obligations, Convertible Note Payable, Stock Options, Unvested RSUs and Warrants [Member]              
Antidilutive securities         8,387,347 9,983,548